Understand the source comparison
Peptides for TBI: Research Compound Comparison
Cerebrolysin BDNF/NGF upregulation via TrkB receptor binding Yes. Low MW peptides cross disrupted BBB 34% improvement in spatial learning (Morris maze) in controlled cortical impact models 6 RCTs, 1,837 patients. Modest GOS improvement (1.2 points) Most extens
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Cerebrolysin
- BDNF/NGF upregulation via TrkB receptor binding
- Yes. Low MW peptides cross disrupted BBB
- 34% improvement in spatial learning (Morris maze) in controlled cortical impact models
- 6 RCTs, 1,837 patients. Modest GOS improvement (1.2 points)
- Most extensive evidence base but effect size remains clinically modest
- Dihexa
- HGF/c-Met pathway potentiation → dendritic spine growth
- Yes. Lipophilic structure allows passive diffusion
- 41% increased dendritic density in CA1 neurons; 28% faster Barnes maze acquisition
- No human trials as of 2026. IND applications active
- Strongest preclinical cognitive outcomes but zero human safety data
- P21 (CNTF derivative)
- Microglial activation suppression via JAK/STAT3 modulation
- Yes. Intranasal delivery bypasses BBB
- 47% reduction in activated microglia (Iba1+ cells) at 7-day post-injury
- Phase IIa (n=64) showed symptom reduction but no cognitive improvement
- Anti-inflammatory mechanism proven but limited to symptom management
- Thymalin
- Immune modulation through thymic peptide pathways
- Limited. Peripheral immune effects predominate
- Reduced systemic IL-6 by 38% in polytrauma models with TBI component
- Observational studies only. No controlled TBI trials
- Peripheral immune effects may reduce systemic inflammation burden
- Cartalax
- Transcriptional regulation through short peptide sequences
- Unknown. Limited pharmacokinetic data
- Preliminary data suggest cartilage and connective tissue effects. Minimal CNS research
- No TBI-specific studies published
- Insufficient evidence for TBI applications. Mechanism unrelated to neuroprotection